Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_assertion description "[Expression of NH(2) terminally truncated BARD1 was correlated with advanced stage of cancer, and expression of spliced isoforms was typical for clear cell carcinoma, the ovarian cancer with worst prognosis, suggesting a role of BARD1 isoforms in cancer progression.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_assertion evidence source_evidence_literature NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_assertion SIO_000772 18089818 NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_assertion wasDerivedFrom befree-20140225 NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_assertion wasGeneratedBy ECO_0000203 NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.
- befree-20140225 importedOn "2014-02-25" NP302609.RADML5xdoKlEGz5gBnXJpPgZLDN1s1eqlLtABbqlJ3dVo130_provenance.